Brief: Evaxion Biotech A/S Receives FDA Fast-Track Designation For Personalized Cancer Immunotherapy
19/01/2023 13:47
Jan 19 (Reuters) - Evaxion Biotech A/S EVAX.O :
* EVAXION RECEIVES FDA FAST-TRACK DESIGNATION FOR
PERSONALIZED
CANCER IMMUNOTHERAPY
Source text for Eikon: ID:nGNXc37p8M
Further company coverage: EVAX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Evaxion A/S
See all newsEvaxion A/S reports results for the quarter ended June 30 - Earnings Summary
Denmark's Evaxion Q2 net loss narrows on lower expenses
Brief: Evaxion Q2 Basic EPS USD -0.01
Evaxion A/S expected to post a loss of 31 cents a share - Earnings Preview
Brief: Evaxion A/S - Expands Pipeline Of Cancer Vaccine Programs With Evx-05 Against Brain Cancer Glioblastoma